Login / Register|Track Order
Drug Discovery Intelligence

From Target to Therapy, Faster.

We combine a proprietary database of 5,000+ validated oncology targets with end-to-end NGS bioinformatics — so your team spends less time on literature review and more time advancing candidates.

5,000+
Curated marker genes across 5 solid tumors
100%
Manually validated from published literature
🧬
Drug Repurposing Maps
Existing approved drugs mapped to all 5,000 gene targets
What We Offer

Three ways to accelerate
your drug discovery pipeline

Whether you need a curated database, custom bioinformatics analysis, or a prioritized target report — we deliver research-grade intelligence built on experimentally validated data.

🗄️

Target & Drug Repurposing Database

Access our proprietary database of 5,000+ oncology genes — each manually curated, prioritized by druggability tier, and mapped to existing approved drugs for repurposing.

  • ✓Diamond, Gold, Silver, Bronze target classifications
  • ✓Druggability annotations with evidence levels
  • ✓Approved drug ↔ gene target repurposing maps
  • ✓Targeting mechanism data (small molecule, antibody, etc.)
  • ✓Searchable by disease area, gene, or drug
🧬

NGS Bioinformatics Services

From raw sequencing data to actionable insights. Our team builds and runs custom NGS pipelines tailored to your research — RNA-seq, WES, WGS, and beyond.

  • ✓End-to-end pipeline design and execution
  • ✓Differential gene expression analysis
  • ✓Variant calling and annotation
  • ✓Pathway and gene ontology enrichment
  • ✓Publication-ready figures and reports
📋

Custom Target Prioritization Reports

Tell us your disease area and therapeutic hypothesis. We deliver a curated report with ranked targets, repurposing candidates, and the supporting evidence — ready for your discovery team.

  • ✓Disease-specific target shortlists
  • ✓Competitive landscape analysis per target
  • ✓Literature evidence summaries
  • ✓Repurposing candidates with rationale
  • ✓Delivered within 2–4 weeks
Proprietary Classification

How we rank targets

Every gene in our database is classified into a druggability tier based on experimental validation, published evidence, and existing drug availability.

💎

Diamond Target

Strong experimental evidence, high druggability, existing approved/pipeline drugs. Highest confidence for therapeutic intervention.

🥇

Gold Target

Solid evidence base, known druggable domains, repurposing opportunities identified from existing pharmacopoeia.

🥈

Silver Target

Emerging evidence, potential druggable features, requires additional validation but showing strong biological rationale.

🥉

Bronze Target

Preliminary associations, early-stage evidence. Included for completeness and to support exploratory research programs.

Sample Database Output

Illustrative example — actual database contains 5,000+ entries

GeneTierDruggableRepurposingIndication
EGFRDiamondYesErlotinib, GefitinibLung Adeno.
KRASDiamondYesSotorasibPancreatic
TP53GoldLimitedUnder investigationColorectal
FGFR2GoldYesErdafitinibH&N Carcinoma
CDK12DiamondYesDinaciclibSCLC
Coverage

Disease areas in our database

Five high-impact solid tumor types with curated gene sets. Expanding to additional cancer types and therapeutic areas.

🫁

Lung Adenocarcinoma

1,000+ genes

🫁

Small Cell Lung Cancer

1,000+ genes

🔬

Colorectal Carcinoma

1,000+ genes

🧫

Head & Neck Carcinoma

1,000+ genes

🔬

Pancreatic Ductal Adenocarcinoma

1,000+ genes

NGS Pipeline

Our bioinformatics workflow

End-to-end analysis from raw sequencing files to prioritized therapeutic targets — with human validation at every stage.

1

Data Intake

FASTQ files, BAM/CRAM, or raw sequencer output from your NGS platform

2

QC & Alignment

Quality control, adapter trimming, and reference genome alignment

3

Analysis

Variant calling, differential expression, pathway enrichment

4

Target Mapping

Cross-reference with our 5,000-gene database for druggability and tier classification

5

Deliverables

Prioritized target list, repurposing candidates, publication-ready report

Why Sri Saradi

What sets us apart

01

Manually Curated

Every gene validated against published literature and experimental data. No automated scraping, no unverified predictions.

02

Pharma R&D Lineage

Our team brings hands-on experience from GMP pharmaceutical R&D environments — we understand what drug development teams actually need.

03

Full Stack Capability

From reagent supply to sequencing analysis to target prioritization — a single partner across your entire discovery workflow.

04

Repurposing Focus

Our drug repurposing maps accelerate timelines by identifying existing approved molecules with evidence for new indications.

Ready to accelerate your
target discovery?

Whether you need database access, a bioinformatics pipeline, or a custom target report — let's discuss how we can support your research.

Schedule a Call →Download Capability Deck